We present an infant with severe familial hyperinsulinism in whom glucose production rate, lipolysis, and gluconeogenesis from glycerol were measured by use of glucose and glycerol labelled with stable isotopes. Administration of a single dose of glucagon (0.1 mg/kg) caused an increase in glucose production rate by near 140% from 4.2 to 10.1 mg·kg–1·min–1. The rate of appearance of glycerol, reflecting the rate of lipolysis, decreased from 15.1 to 12.6 µmol· kg–1·min–1. The amount of glycerol converted to glucose by gluconeogenesis was 9.1 µmol·kg–1·min–1 before and 10.5 µmol·kg–1·min–1 after glucagon administration. We conclude that the marked rise in glucose production rate was mainly the result of increased glycogenolysis. Following the trial, the child was started on long-acting (zinc-protamine) glucagon which made it possible to discontinue intravenous treatment with glucose.

Keywords:
Familial hyperinsulinism, infant, Glucagon, Stable isotope, Glucose production, Glycerol, Nesidioblastosis
1.
Thomas PM, Cote GJ, Wohlik N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995;268:426–429.
2.
Glaser B, Chiu KC, Anker R, Nestorowicz A, Landau H, Ban-Bassat H, Shlomai Z, Kaiser N, Thornton PS, Stanley CA, Spielman RS, Gogolin-Ewens K, Cerasi E, Baker L, Rice J, Donis-Keller H, Permutt MA: Familial hyperinsulinism maps to chromosome 11p14–15.1 30 cM centromeric to the insulin gene. Nat Genet 1994;7:185–188.
3.
Thornton PS, Summer AE, Ruchelli ED, Spielman RS, Baker L, Stanley CA: Familial and sporadic hyperinsulinism: Histologic finding and segregation analysis support a single autosomal recessive disorder. J Pediatr 1991;119:721–724.
4.
Landau H, Schiller M: Persistent hyperinsulinemic hypoglycemia of infance and childhood; in Schiller M (ed): Pediatric Surgery of the Liver, Pancreas and Spleen. Philadelphia, Saunders, 1991, pp 187–201.
5.
Aynsley-Green A, Polak JM, Bloom SR, Gough MH, Keeling J, Ashcroft SJ, Turner RC, Baum JD: Nesidioblastosis of the pancreas: Definition of the syndrome and the management of the severe neonatal hyperinsulinaemic hypoglycemia. Arch Dis Child 1981;56:496–508.
6.
Baker L, Thornton PS, Stanley CA: Management of hyperinsulinism in infants. J Pediatr 1991;119:755–757.
7.
Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA: Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993;123:637–643.
8.
Daneman D, Ehrlich RM: The enigma of persistent hyperinsulinemic hypoglycemia of infancy. J Pediatr 1993;123:573–575.
9.
Rose SR, Chrousos G, Cornblath M, Sidbury J: Management of postoperative nesidioblastosis with zinc protamine glucagon and oral starch. J Pediatr 1986;108:97–100.
10.
Aynsley-Green A, Polak JM, Bloom SR: Nesidioblastosis of the pancreas in the infancy. Dev Med Child Neurol 1981;23:372–379.
11.
Kuhl C, Hvorslev V, Tygstrup I, Lindkaer-Jensen S: Elevated serum proinsulin in beta cell nesidioblastosis: Report of a case in a newborn. Scand J Gastroenterol 1979;53(suppl):49–52.
12.
Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P: An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age. Acta Paediatr Scand 1991;80:756–762.
13.
Hocking MD, Newell SJ, Ranyer PH: Use of human growth hormone in treatment of nesidioblastosis in a neonate. Arch Dis Child 1986;61:706–707.
14.
Food and Drug Administration: Guideline on Validation of the Limulus Amebocyte Lysate Test as End-product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products and Medical Devices. Washington, Food and Drug Andministration, 1987.
15.
Sunehag A, Ewald U, Larsson A, Gustaffson J: Glucose production rat ein extremely immature neonates (<28 weeks) studied by the sue of deuterated glucose. Pediatr Res 1993;33:97–100.
16.
Fjeld CR, Cole FS, Bier DM: Energy expenditure, lipolysis and glucose production in preterm infants treated with theophylline. Pediatr Res 1992;32:693–698.
17.
Sunehag A, Ewald U, Gustafsson J: Extremely preterm infants are capable of gluconeogenesis from glycerol on their first day of life. Pediatr Res 1996;40:553–557.
18.
Mehta A, Wootton R, Cheng KN, Penfold P, Halliday D, Stacey TE: Effect of diazoxide or glucagon on hepatic glucose production rate during extreme neonatal hypoglycemia. Arch Dis Child 1987;62:924–930.
19.
Bourgnères PF, Karl IE, Hillman LS, Bier DM: Lipid transport in the human newborn: Palmitate and glycerol turnover and the contribution of glycerol to neonatal hepatic glucose output. J Clin Invest 1982;70:262–270.
20.
Patel D, Kalhan S: Glycerol metabolism and triglyceride-fatty acid cycling in the human newborn: Effect of maternal diabetes and intrauterine growth retardation. Pediatr Res 1992;31:52–58.
21.
Lindley KJ, Dunne MJ, Kane C, Shepherd RM, Squires PE, James RFL, Johnson PRV, Eckhardt S, Wakeling E, Dattani M, Milla PJ, Aynsley-Green A: Ionic control of β-cell function in nesidioblastosis: A possible therapeutic role for calcium channel blockade. Arch Dis Child 1996;74:373–378.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.